Eduardo Rios-Garcia

Eduardo Rios-Garcia

Auto-generated profile, based on publicly available information

Eduardo Rios-Garcia

Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
LLLuís Felipe Leite
Luís Felipe Leite
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
ESErick F. Saldanha
Erick F. Saldanha
SMSamuel Menezes
Samuel Menezes
AMAndreia C. De Melo
Andreia C. De Melo
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
Cancer is a leading cause of death in Latin America and the Caribbean (LAC), and up-to-date estimates are essential to guide cancer policy. Using GLOBOCAN 2022 data, we analyzed cancer incidence and mortality across 32 LAC countries, calculated age-standardized rates, and assessed early-onset cancer (diagnosed at ages 15–50 years). Mortality-to-incidence ratios were used as a proxy for survival, joinpoint regression estimated annual percent change, and linear regression evaluated correlation between the Human Development Index and cancer indicators. In 2022, LAC recorded 1,551,060 new cancer cases (age-standardized incidence rate, 186.6 per 100,000) and 749,242 deaths (age-standardized mortality rate, 85.2 per 100,000). Prostate and breast cancers were the most common malignancies, whereas lung and breast cancers caused the highest mortality. Mortality declined for prostate cancer [annual percent change, −1.52; 95% confidence interval (CI), −1.80 to −1.24] and male lung cancer (−2.50; 95% CI, −2.68 to −2.33) but increased for female lung (+1.88; 95% CI, 1.71–2.05) and colorectal cancer (+2.48; 95% CI, 2.30–2.67). Human Development Index showed an inverse correlation with mortality-to-incidence ratio (P < 0.001), suggesting improved survival with higher development. Early-onset cancers represented 17% of new cases and 11% of deaths. These findings reveal a growing cancer burden and that persistent disparities in cancer epidemiology persist across LAC, highlighting the urgent need for targeted cancer control strategies and regional cancer control plans. Significance: These findings highlight the urgent need for equity-focused cancer control policies, improved early detection, and expanded access to essential cancer care in the region.

16 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
OAOscar Arrieta
Oscar Arrieta
LLLuis Lara-Mejía
Luis Lara-Mejía
EREduardo Rios-Garcia
Eduardo Rios-Garcia
ECEnrique Caballé-Perez
Enrique Caballé-Perez
LCLuis Cabrera-Miranda
Luis Cabrera-Miranda
RRRafael Rosell
Rafael Rosell
Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy. This phase 2 trial investigates whether combining alectinib with bevacizumab can delay resistance mechanisms in advanced ALK-rearranged NSCLC. ALEK-B was an open-label, single-arm, single-center phase 2 trial (NCT03779191) evaluating alectinib (600 mg BID) and bevacizumab (15 mg/kg) in patients with advanced ALK-rearranged NSCLC confirmed by next-generation sequencing. The primary endpoint was the 12-month progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), intracranial progression-free survival (icPFS), safety, and patient-reported quality of life (QoL). Between April 2020 and August 2022, 41 patients were enrolled, including 17.1% with brain metastases. As of December 14, 2023, with a median follow-up of 34.5 months, the 12-month PFS rate was 97.1% (95% CI 92.6–100). The 36-month PFS and OS rates were 64.2% (95% CI 56.1–85.2) and 87.9% (95% CI 74–96.6), respectively. The ORR was 100%, and the 36-month icPFS rate was 87.8% (95% CI 74.0–96.6). Grade 3–4 adverse events occurred in 46.3% of patients, most commonly proteinuria and hepatotoxicity, with no fatal events reported. QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC.

20 March 2025 in Archives of Medical Research
Verified
Journal Article
Closed access
OAOscar Arrieta
Oscar Arrieta
CPCittim B. Palomares-Palomares
Cittim B. Palomares-Palomares
AGAna Pamela Gómez-García
Ana Pamela Gómez-García
EREduardo Rios-Garcia
Eduardo Rios-Garcia
JHJuan-Manuel Hernandez-Martinez
Juan-Manuel Hernandez-Martinez
ACAndrés F. Cardona
Andrés F. Cardona

12 March 2026 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LCLuis Cabrera-Miranda
Luis Cabrera-Miranda
FMFederico Maldonado
Federico Maldonado
EREduardo Rios-Garcia
Eduardo Rios-Garcia
JTJenny G. Turcott
Jenny G. Turcott
ECEnrique Caballé-Perez
Enrique Caballé-Perez
OAOscar Arrieta
Oscar Arrieta

18 June 2026
Verified
Other
Open access
LLLuís Felipe Leite
Luís Felipe Leite
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
ESErick F. Saldanha
Erick F. Saldanha
SMSamuel Menezes
Samuel Menezes
AMAndreia C. De Melo
Andreia C. De Melo
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
Absolute counts of cases and deaths with corresponding ASIR and ASMR rates, stratified by cancer type and sex across all age groups, for the year 2022.

18 June 2026
Verified
Other
Open access
LLLuís Felipe Leite
Luís Felipe Leite
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
ESErick F. Saldanha
Erick F. Saldanha
SMSamuel Menezes
Samuel Menezes
AMAndreia C. De Melo
Andreia C. De Melo
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
Figure S5. ASMR in LAC countries by cancer type in patients with early-onset cancer, 1990–2022.